ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Blontuvetmab

Its studies are mostly in Acne Vulgaris, led by Arctic Therapeutics.

Furthest: phase 2, since Aug 2, 20261 company-led study, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Arctic Therapeutics10 open or runningphase 2since Aug 2, 2026Aug 2, 2026none ahead

Also a collaborator on its studies: Blueskin AS.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2015Named blontuvetmabINNProposed as its International Nonproprietary Name in WHO's List 114 · before, AT-004
  2. Aug 2, 2026First study: phase 2 study in Acne VulgarisFirst studyNCT07774364 · 63 enrolled · Denmark

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07774364Acne Vulgaris · Denmark2CompletedJul 15, 202663

How it is read

Names in the registry

  • “AT-004”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.